Skip to content
Contact Us

COMPLIANT PROGRAMS WITHOUT BUILDING
THE INFRASTRUCTURE YOURSELF

Direct To Patient

Neovance Direct-to-Patient solutions give manufacturers a fully managed, configurable model for launching compliant cash-pay and direct-to-patient programs.



We connect patient engagement, payment processing, prescription workflows, fulfillment, and reporting into one streamlined operating model.

End-to-End DTP infrastructure

Branded Digital Engagement

Manufacturer-branded experiences that support patient education, onboarding, consent, and engagement.

Payment & Patient Verification

Secure payment processing, consent management, and identity verification integrated directly into the patient workflow.

Prescription Intake & Workflow Management

Flexible prescription pathways, including ePrescribing, faxed prescriptions, and telehealth partner connectivity.

Nationwide Pharmacy Fulfillment

Specialty pharmacy fulfillment across all 50 states and U.S. territories, with support for ambient, cold-chain, and controlled-substance therapies.

Omnichannel Patient Engagement

SMS, email, and live support communications designed to keep patients informed and engaged.

Reporting & Program Visibility

Operational dashboards and analytics that provide visibility into patient engagement, fulfillment, and program performance.

Why Neovance:

  • Configurable DTP programs that can launch in as little as 12–16 weeks

  • Fully managed infrastructure without internal buildout

  • Nationwide specialty pharmacy licensure across all 50 states and U.S. territories

  • Redundant fulfillment infrastructure designed for continuity and scalability

  • Support for ambient, cold-chain, and controlled-substance therapies

  • Transparent reporting and compliance oversight

Whitepaper

Convenience Wins:

How DTP Is Reshaping the Pharma Commercial Model

As consumer expectations and policy pressures converge, Direct-to-Patient models are reshaping pharmaceutical access from optional to essential. Convenience Wins by Ty Hessexamines why DTP is quickly becoming a baseline requirement for competitive pharma commercialization.

Read More